清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

赛马鲁肽 医学 磷酸西他列汀 耐受性 中止 临床终点 杜拉鲁肽 内科学 艾塞那肽 2型糖尿病 随机对照试验 利拉鲁肽 糖尿病 不利影响 磷酸西他列汀 内分泌学
作者
Thomas R. Pieber,Bruce W. Bode,Ann C. Mertens,Young Min Cho,Erik Christiansen,CHRISTIN L. HERTZ,Signe Olrik Rytter Wallenstein,John B. Buse,Serkan Akın,Nesim Aladağ,Ahmed A. Arif,Louis J. Aronne,S Aronoff,Hayriye Esra Ataoğlu,Sei Hyun Baik,Harold Bays,Patricia Beckett,Dilek Berker,Stefan Bilz,Bruce W. Bode
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:7 (7): 528-539 被引量:209
标识
DOI:10.1016/s2213-8587(19)30194-9
摘要

Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglutide with sitagliptin 100 mg.In this 52-week, multicentre, randomised, open-label, phase 3a trial, we recruited patients with type 2 diabetes from 81 sites in ten countries. Patients were eligible if they were aged 18 years or older (19 years or older in South Korea), had type 2 diabetes (diagnosed ≥90 days before screening), HbA1c of 7·5-9·5% (58-80 mmol/mol), and were inadequately controlled on stable daily doses of one or two oral glucose-lowering drugs (for 90 days or more before screening). Participants were randomly assigned (1:1) by use of an interactive web-response system, stratified by background glucose-lowering medication at screening, to oral semaglutide with flexible dose adjustments to 3, 7, or 14 mg once daily or sitagliptin 100 mg once daily. To approximate treatment individualisation in clinical practice, oral semaglutide dose could be adjusted on the basis of prespecified HbA1c and tolerability criteria. Two efficacy-related estimands were prespecified: treatment policy (regardless of treatment discontinuation or use of rescue medication) and trial product (on treatment and without use of rescue medication) for participants randomly assigned to treatment. The primary endpoint was achievement of HbA1c of less than 7% (53 mmol/mol) at week 52 and the confirmatory secondary efficacy endpoint was change in bodyweight from baseline to week 52. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02849080, and European Clinical Trials Database, EudraCT number 2015-005593-38, and an open-label extension is ongoing.Between Sept 20, 2016, and Feb 7, 2017, of 804 patients assessed for eligibility, 504 were eligible and randomly assigned to oral semaglutide (n=253) or sitagliptin (n=251). Most participants were male (285 [57%] of 504) with a mean age of 57·4 years (SD 9·9). All participants were given at least one dose of their allocated study drug except for one participant in the sitagliptin group. From a mean baseline HbA1c of 8·3% (SD 0·6%; 67 mmol/mol [SD 6·4]), a greater proportion of participants achieved an HbA1c of less than 7% with oral semaglutide than did with sitagliptin (treatment policy estimand: 58% [134 of 230] vs 25% [60 of 238]; and trial product estimand: 63% [123 of 196] vs 28% [52 of 184]). The odds of achieving an HbA1c of less than 7% was significantly better with oral semaglutide than sitagliptin (treatment policy estimand: odds ratio [OR] 4·40, 95% CI 2·89-6·70, p<0·0001; and trial product estimand: 5·54, 3·54-8·68, p<0·0001). The odds of decreasing mean bodyweight from baseline to week 52 were higher with oral semaglutide than with sitagliptin (estimated mean change in bodyweight, treatment policy estimand: -2·6 kg [SE 0·3] vs -0·7 kg [SE 0·2], estimated treatment difference [ETD] -1·9 kg, 95% CI -2·6 to -1·2; p<0·0001; and trial product estimand: -2·9 kg [SE 0·3] vs -0·8 kg [SE 0·3], ETD -2·2 kg, -2·9 to -1·5; p<0·0001). Adverse events occurred in 197 (78%) of 253 participants in the oral semaglutide group versus 172 (69%) of 250 in the sitagliptin group, and nausea was the most common adverse event with oral semaglutide (53 [21%]). Two deaths occurred in the sitagliptin group during the trial.Oral semaglutide, with flexible dose adjustment, based on efficacy and tolerability, provided superior glycaemic control and weight loss compared with sitagliptin, and with a safety profile consistent with subcutaneous GLP-1 receptor agonists.Novo Nordisk A/S.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助和谐乌龟采纳,获得10
19秒前
26秒前
31秒前
mo发布了新的文献求助10
31秒前
42秒前
雪山飞龙完成签到,获得积分10
46秒前
47秒前
benzene完成签到 ,获得积分10
56秒前
5433完成签到 ,获得积分10
57秒前
KINGAZX完成签到 ,获得积分10
57秒前
muriel完成签到,获得积分10
1分钟前
小马甲应助傲娇的夜山采纳,获得10
1分钟前
1分钟前
orixero应助Demi_Ming采纳,获得10
1分钟前
1分钟前
可爱的函函应助mo采纳,获得10
1分钟前
科研通AI2S应助雪白小丸子采纳,获得10
1分钟前
傲娇的夜山完成签到,获得积分10
1分钟前
mo完成签到,获得积分20
1分钟前
好天气完成签到 ,获得积分20
1分钟前
好天气关注了科研通微信公众号
1分钟前
领导范儿应助533采纳,获得10
2分钟前
2分钟前
Demi_Ming发布了新的文献求助10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
张哈完成签到 ,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
SciGPT应助科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
和谐乌龟发布了新的文献求助10
3分钟前
葫芦芦芦完成签到 ,获得积分10
3分钟前
张琦完成签到 ,获得积分10
3分钟前
3分钟前
雪白小丸子完成签到,获得积分10
3分钟前
naczx完成签到,获得积分0
3分钟前
喵叽完成签到 ,获得积分20
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968504
求助须知:如何正确求助?哪些是违规求助? 3513331
关于积分的说明 11167297
捐赠科研通 3248697
什么是DOI,文献DOI怎么找? 1794417
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804652